menu toggle

What Does 2020 Hold For Biosimilars? Industry Experts Weigh In

Biosimilar Development

In the first installment of this four-part series, the members of the Biosimilar DevelopmentEditorial Board and friends discussed how 2019 turned out for the biosimilar industry. But as we face 2020, several big questions remain from the past year and about what the future may (or may not) bring for the industry. Here, these 19 experts pose their biggest questions for the new year, as well as how they anticipate or hope these questions could be answered.

For perspective from Rick Lozano,  VP of Biosimilars & Integrated Business Development, check out Biosimilar Development.